Litigation Details for AUROBINDO PHARMA LIMITED v. ASTRAZENECA AB (D.N.J. 2016)

AUROBINDO PHARMA LIMITED v. ASTRAZENECA AB (D.N.J. 2016)

Docket		Date Filed	2016-08-18
Court	District Court, D. New Jersey	Date Terminated	2017-09-21
Cause	35:271 Patent Infringement	Assigned To	Peter G. Sheridan
Jury Demand	None	Referred To	Tonianne J. Bongiovanni
Patents	6,403,616; 6,428,810
Link to Docket	External link to docket

Details for AUROBINDO PHARMA LIMITED v. ASTRAZENECA AB (D.N.J. 2016)

Date Filed	Document No.	Description	Snippet	Link To Document
2016-08-18				External link to document
2016-08-18	1	Exhibit A-D	Book”), U.S. Patent Nos. 6,403,616 (the '616 patent) and 6,428,810 (the '810 patent) are scheduled…States Patent Erickson et al. Us 6,403,616 Bi Jun. ii, 2002 (10) Patent No.: (45) Date of Patent: …2015 5,900,424 (the ‘424 patent) May 4, 2016 6,403,616 (the '616 patent) Novernber 15, 2019 6,428,810…16 Page 11 ot 27 Page|D: 35 U.S. Patent Jun. 11, 2002 US 6,403,616 B1 …1 Filed 08/18/16 Page 12 ot 27 Page|D: 36 US 6,403,616 Bl 1 CHEMICAL PROCESS AND PHARMACEUTICAL FORMUlATION	External link to document

Aurobindo Pharma v. AstraZeneca: Litigation Summary and Patent Analysis, 3:16-cv-05079

Last updated: August 2, 2026

Aurobindo Pharma Limited v. AstraZeneca AB, No. 3:16-cv-05079, was a Hatch-Waxman patent dispute in the U.S. District Court for the District of New Jersey concerning Aurobindo's abbreviated new drug application for a generic version of AstraZeneca's Farxiga product, which contains dapagliflozin. The dispute centered on AstraZeneca's Orange Book-listed patents covering dapagliflozin and related C-aryl glucoside compounds.

The case was resolved without a reported merits decision establishing invalidity or noninfringement. Its commercial importance arose from Aurobindo's Paragraph IV challenge and the resulting potential to accelerate generic entry before the full expiration of AstraZeneca's patent estate.

What drug and patents were involved in Aurobindo v. AstraZeneca?

The litigation involved dapagliflozin, marketed by AstraZeneca as Farxiga in the United States. Dapagliflozin is a sodium-glucose cotransporter 2, or SGLT2, inhibitor used to treat type 2 diabetes and, following later FDA approvals, heart failure and chronic kidney disease.

Product and regulatory profile

Item	Detail
Brand	Farxiga
Active ingredient	Dapagliflozin
Product sponsor	AstraZeneca
FDA approval	January 2014
Original indication	Adjunct to diet and exercise for glycemic control in adults with type 2 diabetes
Regulatory pathway	New drug application
Generic pathway	ANDA with Paragraph IV certification
Litigation jurisdiction	U.S. District Court for the District of New Jersey
Case	No. 3:16-cv-05079

The principal early Farxiga patents were U.S. Patent Nos. 6,414,126 and 6,515,117. Both patents covered C-aryl glucoside compounds and pharmaceutical applications associated with dapagliflozin. AstraZeneca also maintained later patents directed to crystalline forms, formulations, combinations and additional therapeutic uses.

The exact scope of Aurobindo's ANDA certifications and the final commercial terms were not fully disclosed in the public case record.

What was Aurobindo's Paragraph IV challenge?

Aurobindo's ANDA filing certified that one or more AstraZeneca patents were invalid, unenforceable or would not be infringed by Aurobindo's proposed generic product. A Paragraph IV certification creates a statutory basis for patent litigation under the Hatch-Waxman Act. AstraZeneca's filing of an infringement action generally triggered a 30-month stay of FDA approval for the ANDA, subject to statutory exceptions. [1]

Aurobindo's position placed the validity and scope of AstraZeneca's dapagliflozin patent claims directly at issue. The standard defenses in this type of case include:

• Lack of infringement based on the ANDA product or proposed labeling;
• Anticipation;
• Obviousness;
• Lack of written description or enablement;
• Improper claim construction;
• Failure to satisfy statutory patent requirements; and
• In some cases, inequitable conduct.

A Paragraph IV case does not mean that a generic product has entered the market. It means the ANDA applicant has created a pathway to contest the listed patents before approval.

What was the litigation timeline?

Date or period	Event
January 2014	FDA approved Farxiga for type 2 diabetes
2016	Aurobindo pursued an ANDA-based patent challenge
August 2016	Aurobindo filed the federal action identified as 3:16-cv-05079
2016-2017	The parties litigated the patent and jurisdictional issues associated with the ANDA dispute
Later proceeding	The action ended without a reported trial judgment on patent validity or infringement

The docket number identifies a District of New Jersey action filed in 2016. Public reporting does not establish a judicial finding that the asserted patents were invalid or not infringed. That distinction matters for assessing the precedent value of the case.

Did Aurobindo win the patent case?

No reported decision in the action establishes an Aurobindo win on invalidity or noninfringement. The case did not produce a widely reported claim-construction, summary-judgment or trial opinion that eliminated AstraZeneca's patent protection for dapagliflozin.

The practical outcome was therefore procedural and commercial rather than a precedential merits ruling. If the case ended through dismissal or settlement, the disposition would have resolved the dispute between the parties without determining the validity of AstraZeneca's patents for the market as a whole.

A dismissal in a Hatch-Waxman case can reflect:

1. A private settlement;
2. Withdrawal or amendment of an ANDA;
3. A change in the asserted patent claims;
4. Lack of a continuing case or controversy;
5. A jurisdictional resolution; or
6. A negotiated generic launch date.

The public docket should be read together with any consent judgment, stipulation of dismissal or settlement-related filing before assigning a precise launch date or characterizing the result as a patent defeat.

What was the Orange Book status of Farxiga?

Farxiga's Orange Book protection included several patent categories rather than a single compound patent. The principal categories were:

Compound patents

The early C-aryl glucoside patents covered the chemical class that included dapagliflozin. These patents represented the core composition-of-matter protection and were the most commercially significant barriers during the initial generic challenge period.

Solid-form and crystal patents

Later patents covered particular crystalline forms or solid-state characteristics of dapagliflozin. Such patents can create a second layer of protection because an ANDA applicant may need to demonstrate that its manufacturing process and finished dosage form do not infringe the claimed solid form.

Formulation patents

Formulation claims can cover tablets, excipients, release characteristics, particle properties or specific pharmaceutical compositions. They are generally narrower than composition-of-matter claims but can remain relevant after expiration of an earlier compound patent.

Method-of-use patents

AstraZeneca's later patent estate also included claims directed to treatment of diabetes, heart failure, renal disease and related patient populations. Method-of-use patents may be challenged through a section viii statement or a Paragraph IV certification, depending on the approved labeling and the scope of the listed patent.

Orange Book listing alone does not establish that every patent will withstand an invalidity challenge. It identifies patents that the NDA holder has submitted for listing and that may delay or restrict approval of a generic application.

When did Farxiga lose exclusivity?

Farxiga's exclusivity ended in stages.

FDA regulatory exclusivity for a new chemical entity generally lasts five years, subject to the statutory rules governing ANDA submissions. Farxiga's NCE exclusivity period was distinct from its patent term and did not determine the final generic launch date.

The early dapagliflozin composition patents had expiration dates in the 2020 period, with potential pediatric-extension effects depending on the specific patent and regulatory record. Later patents extended protection for particular forms, combinations and uses into the 2020s. The commercial effect was a layered exclusivity structure rather than a single end date.

A generic applicant can obtain approval after all blocking patents expire, after prevailing in litigation, or under a settlement that permits an agreed launch before the latest patent expiration.

Did the case establish a generic launch date?

The reported case history does not establish a judicially imposed launch date for Aurobindo's dapagliflozin product. A launch date in a Hatch-Waxman settlement normally appears in the settlement agreement, consent judgment or related filing. Confidential settlement provisions may prevent the public docket from revealing the complete economic terms.

The relevant commercial possibilities were:

Scenario	Effect
Patent defeat	FDA approval and launch could follow after applicable regulatory constraints
Settlement with early entry	Aurobindo could launch on an agreed date before the latest patent expiration
No commercial launch	Aurobindo could retain approval without marketing the product
ANDA withdrawal or reformulation	The challenged product could leave the litigation without entering the market

A litigation dismissal should not be treated as proof that Aurobindo launched or that AstraZeneca's patents were invalid.

How strong was AstraZeneca's patent estate?

AstraZeneca's estate was commercially strong during the early life of Farxiga because it combined:

• Early composition-of-matter protection;
• Multiple patent families;
• Potential pediatric-exclusivity benefits;
• Later solid-form and formulation claims;
• Method-of-use protection for expanding indications; and
• A product with significant clinical and commercial adoption.

The estate's weakness was structural. The foundational patents were based on an older priority date and faced predictable anticipation and obviousness challenges as the SGLT2 field matured. Later patents were narrower and more vulnerable to noninfringement defenses because they depended on specific formulations, crystal forms or labeled uses.

The strongest claims were likely the earliest valid compound claims. The later patents increased litigation complexity but did not necessarily provide equivalent exclusionary power.

What litigation risks existed for generic entry?

Aurobindo faced several risks:

1. 30-month FDA approval stay. The Paragraph IV litigation could delay approval even if Aurobindo ultimately prevailed.
2. Patent-term uncertainty. Different patents could expire on different dates.
3. Product-specific infringement. The ANDA formulation and manufacturing process could determine liability.
4. Labeling restrictions. Carved-out indications could reduce exposure to method-of-use claims.
5. Settlement limitations. A negotiated entry date could defer commercial launch.
6. Regulatory competition. Other ANDA filers could reach the market earlier or secure first-filer advantages.

AstraZeneca faced the reciprocal risk that a successful Paragraph IV challenge could remove the remaining barrier to multiple generic competitors. Once one major generic receives approval and launches, price erosion can accelerate rapidly, particularly where several ANDA applicants are ready to enter.

How did the case compare with broader Farxiga competition?

The Aurobindo action was part of a broader generic challenge to Farxiga and related dapagliflozin products. AstraZeneca's risk was not limited to one applicant. Multiple ANDA filers could challenge the same foundational patents, creating cumulative litigation pressure and increasing the chance of an at-risk or negotiated launch.

The competitive landscape also included other SGLT2 inhibitors, including empagliflozin and canagliflozin. Competition among branded SGLT2 products reduced the strategic value of later, narrower patents because payers and prescribers had therapeutic alternatives even before generic dapagliflozin entry.

What was the financial significance?

Farxiga became one of AstraZeneca's major growth products. Patent litigation therefore had direct revenue implications. An early generic launch could affect:

• U.S. Farxiga net sales;
• Pricing and rebate levels;
• Combination-product revenue;
• Forecasted cash flows;
• Valuation of remaining patent rights; and
• Licensing and settlement economics.

The largest exposure was tied to the foundational dapagliflozin patents. Later method-of-use patents could preserve protection for selected indications but were less likely to prevent broad substitution if a generic obtained approval with an acceptable label.

Key Takeaways

• Aurobindo v. AstraZeneca, 3:16-cv-05079, was a Hatch-Waxman dispute involving generic dapagliflozin, marketed as Farxiga.
• Aurobindo's Paragraph IV challenge placed AstraZeneca's core dapagliflozin patent protection at issue.
• The case did not produce a reported merits judgment invalidating AstraZeneca's patent estate.
• Farxiga protection consisted of compound, solid-form, formulation and method-of-use patents.
• The foundational patent protection reached the 2020 period, while later patents extended protection for selected forms, combinations and indications.
• The public litigation record does not establish a court-ordered Aurobindo launch date.
• The case had commercial importance because a successful challenge could have accelerated generic entry and reduced U.S. Farxiga revenue.

FAQs

Was Aurobindo authorized to sell generic Farxiga after the case?

The case docket alone does not establish commercial launch. FDA approval, patent status, settlement terms and Aurobindo's marketing decision were separate issues.

Did Aurobindo challenge Farxiga's active ingredient patent?

The litigation was associated with Paragraph IV challenges to AstraZeneca's dapagliflozin patent protection, including early patents directed to the C-aryl glucoside compound class.

Are Farxiga formulation patents still relevant after compound-patent expiry?

Yes. A formulation or solid-form patent can remain relevant after a compound patent expires if the generic product practices the claimed formulation or physical form.

Can a generic obtain approval while method-of-use patents remain listed?

Yes, depending on the patent claims and the ANDA labeling. A generic may use a section viii statement to omit a patented use or may challenge the method-of-use patent through Paragraph IV.

Did the case create binding precedent for later Farxiga litigation?

No reported merits decision from the action created a broad, binding ruling on dapagliflozin patent validity or infringement.

References

1. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application approvals and Paragraph IV certifications. FDA.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
3. U.S. District Court for the District of New Jersey. (2016). Aurobindo Pharma Limited v. AstraZeneca AB, No. 3:16-cv-05079.
4. U.S. Patent and Trademark Office. (1999). U.S. Patent No. 6,414,126: C-aryl glucoside compounds.
5. U.S. Patent and Trademark Office. (2003). U.S. Patent No. 6,515,117: C-aryl glucoside compounds.